Linked Life Data

11191068

Source:http://linkedlifedata.com/resource/pubmed/id/11191068

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2001-1-12
pubmed:abstractText
The use of crude cartilage for the treatment of human cancers remains a subject of controversy. In this brief commentary, we reviewed the current knowledge on the anticancer properties of cartilage. We then presented the properties of AE-941, a novel standardized water-soluble extract derived from shark cartilage that represents less than 5% of the crude cartilage. It is a multifunctional antiangiogenic product that contains several biologically active molecules. EA-941 is one of the few antiangiogenic drugs that is under phase III clinical investigation. It is currently evaluated in Europe and North America for the treatment of refractory renal cell carcinoma and in North America for metastatic non small cell lung cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0167-7659
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
83-6
pubmed:dateRevised
2008-6-5
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?
pubmed:affiliation
Laboratoire de médecine moléculaire H pital Ste-Justine-UQAM, Centre de cancérologie Charles-Bruneau, Montreal, Quebec, Canada.
pubmed:publicationType
Journal Article, Review